GVHD Excellence Forum
Leaders in the field sharing authoritative insights and institutional best practices.
Xue-Zhong Yu, MD, MS, MBA, discusses Sirtuin-1 as a possible therapeutic target for the control of GVHD.View More
In a phase 2 clinical trial, ruxolitinib was well-tolerated and led to responses in >50% of patients with steroid-refractory acute GVHD.View More
Ruxolitinib significantly improved efficacy outcomes over common therapy options for patients with glucocorticoid-refractory acute GVHD after allogeneic stem cell transplantation.View More
Oncologists may be able to reduce GVHD preventative measures for pediatric patients with acute leukemia post-HSCT.View More